Literature DB >> 8546736

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

A M van Gestel1, M L Prevoo, M A van 't Hof, M H van Rijswijk, L B van de Putte, P L van Riel.   

Abstract

OBJECTIVE: To validate the European League Against Rheumatism (EULAR), the American College of Rheumatology (ACR), and the World Health Organization (WHO)/International League Against Rheumatism (ILAR) response criteria for rheumatoid arthritis (RA).
METHODS: EULAR response criteria were developed combining change from baseline and level of disease activity attained during follow up. In a trial comparing hydroxychloroquine and sulfasalazine, we studied construct (radiographic progression), criterion (functional capacity), and discriminant validity.
RESULTS: EULAR response criteria had good construct, criterion, and discriminant validity, ACR and WHO/ILAR criteria showed only good criterion validity.
CONCLUSION: EULAR response criteria showed better construct and discriminant validity than did the ACR and the WHO/ILAR response criteria for RA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8546736     DOI: 10.1002/art.1780390105

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  463 in total

Review 1.  Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Clinical outcome measures in rheumatoid arthritis.

Authors:  P L van Riel; A M van Gestel
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials.

Authors:  R Rau
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

4.  Intra-individual assessment of inflammatory severity and cartilage composition of finger joints in rheumatoid arthritis.

Authors:  C Schleich; A Müller-Lutz; P Sewerin; B Ostendorf; C Buchbender; M Schneider; G Antoch; F Miese
Journal:  Skeletal Radiol       Date:  2014-11-01       Impact factor: 2.199

5.  Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate.

Authors:  O Sander; G Herborn; E Bock; R Rau
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

6.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

7.  Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

Authors:  R F van Vollenhoven; S Brannemark; L Klareskog
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

8.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

9.  Morning stiffness of the joints is the sole predictor of short-term response to glucocorticoid treatment in active rheumatoid arthritis (RA).

Authors:  C Fiehn; S Kessler; K Müller
Journal:  Rheumatol Int       Date:  2011-09-21       Impact factor: 2.631

10.  Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.

Authors:  Miriam García-Arias; Dora Pascual-Salcedo; Susana Ramiro; Marie-Eve Ueberschlag; Thomas M Jermann; Carlos Cara; Emilio Martín-Mola; Alejandro Balsa
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.